Sign up USA
Proactive Investors - Run By Investors For Investors

Destiny Pharma believes it has the answer to superbug threat

The urgency and size of the market offers huge potential for any company that can come up with a new way to treat infections safely
petri dishes
Destiny says XF-73 is a breakthrough in treating infection

Superbugs are among the most significant health concerns for the world’s governments and medical practitioners. 

The US Department of Health & Human Services and its agency BARDA, for example, routinely hand out millions of dollars in grants to companies working on ways to tackle anti-microbial or antibiotic resistance.

WATCH: Destiny Pharma to push ahead with next-generation antibiotic after $15mln IPO

The urgency and size of the market offers huge potential for any company that can come up with a new way to treat infections safely and Destiny Pharma PLC (LON:DEST) believes it can be the one that does.

An AIM listing in September at 157p raised £15mln. For a small private company to pull in that amount of money underlines both the medical need and opportunity for both its lead drug and other compounds still in the clinic.

Breakthrough in anti-microbial resistance

Neil Clark, a veteran of a couple of AIM listings already before Destiny, explains that its most advanced product XF-73, is potentially a breakthrough in the area of hospital–generated infections.

All the cleaning and hygiene in the world cannot stop an infection called Staphylococcus aureus, he says, which is carried in the nose of 30% of the world’s population and infects an unfortunate few patients when they undergo an operation.

READ: New float Destiny Pharma's shares race to a 30% debut premium

Studies so far, though, indicate the way XF-73 operates makes it different from other anti-microbial agents.

A topical gel that is applied in the nose, it is fast acting and the bacteria is killed within 15 minutes, which means little opportunity to mutate and generate resistance.

In five studies carried out so far on 160 patients, no resistance was identified in four common strains of MRSA, while it proved effective against a whole range of other bacteria ranging from listeria through to C.difficile.

QIDP status

US regulator the Food and Drug Administration granted the drug Qualifying Infectious Disease Product (QIDP) status in 2015 and even established a new indication for the treatment: 'Prevention of post-surgical staphylococcal infections', including MRSA.

QIDP status is reserved for serious or life-threatening infections including those caused by antibiotic resistant pathogens

XF-73’s most recent trial, a Phase I/IIa, was funded by NIAID, the US government's expert division on anti-microbial drugs, and indicated a reduction in the spread of nasal S.aureus in healthy volunteers. 

Before an operation, patients are tested for S.aureus and those with a positive result receive XF-73.

The next step for the drug is a Phase IIB trial, which will establish dosing levels and give a better indication of efficacy.

Around 220 patients will be tested with the results due in the early part of 2019. Proceeds from the AIM listing will cover the cost, says Clark.

One partner has already backed the drug with hard cash. China Medical Systems, a US$4bn Hong Kong-listed drug distributor and marketer, invested £3mln in the IPO and has also set up a collaboration, giving it distribution rights to the XF platform in the Greater China region.

The hospital infection market being targeted by XF-73 is worth around US$1bn, but the additional potential of the platform is also an important part of the future of Destiny, says Clark.

Other possibiities

A variation of XF-73 is under development to tackle the problem of throat-carried S.aureus, which can cause a condition known as ventilator associated pneumonia (VAP)  in patients in intensive care units.

Around 30 other compounds are in the pre-clinical pipeline, the most advanced of which is XF-70, a treatment to stop infections in wounds and burns and potentially skin conditions such as acne.

This has already got the attention of the US military, which has provided some early stage funding.

Destiny is also assessing the XF platform’s effectiveness against biofilms, a new area of research that is being linked with chronic and recurring conditions such as cystic fibrosis.

The pre-clinical pipeline will keep news flowing ahead of the result of the key XF-73 trial, which for all of the pipeline promise will likely be a pivotal moment for Destiny.

Clark is upbeat: “We own the intellectual property, we‘ve raised the money, now we just have to get down to work.”

At 139p, Destiny is valued at £53mln.

View full DEST profile View Profile

Related Articles

June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
June 28 2018
The AIM-listed pharmaceuticals developer said the contract delays meant that its first-half revenue was expected to be “below management’s expectations”
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use